Introduction
L-Dopa (levodopa, 3-4 dihydroxyphenilalanine) is a naturally occurring substance, a precursor of dopamine and thus an integrallink in the catecholamine anabolic pathway. It crosses the blood-brain-barrier and probably exerts its indirect pharmacological action through dopamine (2) . L-Dopa acts in the following three ways: kinetic, psychic and autonomic.
In the past, levodopa has been given in very small amounts 'and for short periods to patients with psycho affective disorders (mainly depression), and it produced contradictory results (4, 12) . The clinical application of levodopa for the treatment of Parkinson's disease and also the concomitant onset of psychiatric symptoms as untoward effects has renewed the interest in this pharmacological agent for psychiatric experimentation. At this research unit, which is attached to the Central Islip State Hospital in the State of New York, the drug trials were performed with L-Dopa on patients with drug-induced Parkinsonism in schizophrenia (15) and also on patients suffering from 'true' Parkinson without mental illness, and numerous psychiatric symptoms resulted. This seemed to warrant further investigation into L-Dopa action and it carried possibilities in support of some aspects of the chemical etiology of schizophrenia. It was therefore decided to study its clinical action on a psychotic population.
Methodology
Fifteen hospitalized psychotic male patients with an age range between 19 VoL 17 (1971) of these patients suffered from schizophrenia and three from alcoholic psychosis.
The study was single blind and was divided into two trials; the first was a pilot study with five patients and the second with ten patients (one patient was repeated from the first group). The project was designed so that all patients remained on their standard neuroleptic medication throughout the study in order to obtain a uniform psychiatric baseline. In addition placebo was administered to seven patients for one week before the L-Dopa treatment and for one week to the remaining patients after the L-Dopa treatment. Levodopa was administered in capsule form twice a day in increased gradual doses up to 2 gm daily, and that dose was maintained for one week.
Complete physical examinations including electrocardiogram (EKG) , electroencephalogram (EEG) and blood and urine chemistries were performed. Psychiatric evaluation included mental examinations, Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), Nurses Observation Scale for Inpatient Evaluation (NOSIE), Treatment Emergent Symptoms (TES), the Hoffer-Osmond Diagnostic test and the Kent-Rosanoff Word Association test. These ratings were conducted at baseline, 1 gm of placebo, 2 gm of L-Dopa, and one week after completion of the study. Concomitantly the physiological parameters of Heart Rate (HR), Galvanic Skin Resistance (GSR) and Respiration Rate (RR) were measured for rest and stress conditions. Stress was obtained by random electrical stimuli.
Results
One patient was eliminated from the study because of vomiting -otherwise no other side effeots or toxic reactions were observed, Psychiatric evaluations depicted modifications in the areas of perception, thought process, attention, orientation, memory, judgment, affect and immediate and long-term behaviour. Eight patients complained of having hallucinations -five of them having had visual misperceptions and three auditory hallucinations. Of these eight patients three had never reported the presence of hallucinations previously and when they did report with L-Dopa two had visual and one auditory hallucinations. The other six patients had an increase in the frequency and severity of hallucinatory material. Also, within the area of perception, mild short-lasting changes in olfaction, gustation and time were recorded.
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Thought process was altered in nine patients and severe paranoid thoughts were observed and recorded in five. The range of attention deteriorated in two patients and another showed discontinuity of thought.
In all the psychotic alcoholic patients and in one schizophrenic patient there was a deterioration of time orientation and in addition all the psychotic alcoholic patients displayed a more severe memory deficit than was present before L-Dopa treatment. Judgment was considered to be impaired in one patient but improvement was seen in another.
The affect and immediate behaviour of three patients became more inappropriate under L-Dopa treatment, six became depressed and three became more alert and active. 
RW. In the sexual sphere three patients manifested an increase of libido, one of whom became concerned over troublesome penile erections, while the other two patients verbally displayed interest in female attendants, who constantly preoccupied their thoughts.
In regard to long-term behaviour, two patients had a loss of appetite, one began to get up earlier, one stopped drinking coffee 'and one changed his grooming habits.
Upon collection of the above mentioned behavioural deviations twenty-three changes were found at the 1 gm dose and twentyeight changes at the 2 gm dose, with six modifications occurring at both dosage levels. This leaves seventeen independent changes of behaviour at 1 gm and twentytwo independent changes of behaviour at 2 gm -see Table I .
Five patients possessed dual modifications at both dosages, one at the 1 gm and 2 gm doses had symptoms of depression and paranoid thoughts, while the other four patients exhibited perceptual, mood and orientation abnormalities at both the 1 and 2 gm doses. Table II indicates each individual's modification at either the 1 or 2 gm dosage.
On the Word Association test eleven patients were testable, while the remaining three did not speak sufficient English. In ten patients communication significantly improved with L-Dopa (Binomial Test, P < .011) although some had a preferential dosage for their best improvement -see Table III . One patient had essentially no change and was observed to hallucinate when tested at the time he was receiving L-Dopa. This impaired his performance, but not enough to decrease his communication and yet not enough to improve it objectively. Subjectively it can be reported that communication in all patients improved -to such an extent that some spontaneously reported their hallucinations.
Response times in communication were dramatically improved in nine patients, while two were slower in responding with L-Dopa, but these two patients although slower to respond did communicate better see Table IV . The physiological results indicated that L-Dopa increased HR in both rest and stress conditions. Contrarily, RR was inconsistent in both conditions. GSR responses were persistent in habituation trials, spontaneous fluctuations were slightly increased in both rest and stress conditions and skin conductance was lower under stress.
Discussion
The administration of L-Dopa to schizophrenic patients resulted in psychiatric and behavioural changes, and these changes were noted by the psychiatrists, ward per- sonnel and, most importantly, by the patients themselves. Based on the pilot study it was decided to keep all patients on their neuroleptic medication, thus avoiding the onset of new symptoms which might be initiated after 'a wash-out period, and securing a steady, well-known psychiatric baseline. The affective and behavioural changes seen in some of these patients varied from depression to happiness, increased activity, optimism and alertness. Two patients with a moderate degree of elation at the 1 gm dose of levodopa became depressed at the 2 gm dose. Thus a biphasic action appears to be present, as was previously observed in animal experimentation (8, 18) . It is also important to remember the concomitant presence of depression in Parkinson's disease, which is difficult to control even after surgery or Ievodopa therapy. Our experience indicates that in Parkinson patients depression is aggravated on L-Dopa therapy. Also, depressive symptoms in schizophrenia overlap or are mistaken for anergia, immobility, detachment and so on, thus creating a diagnostic problem.
As a group the physiological reactions to L-Dopa are similar to stimulant drugs, particularly amphetamine which, as Lader demonstrated, causes an increase in spontaneous fluctuations, persistent responses in habituation and an increased heart rate (14) . Chronic schizophrenic patients usually ex-hibit a Gestalt of low skin conductance, more frequent spontaneous fluctuations and persistent habituation responses -a state of so-called over-arousal. This pattern was seen with L-Dopa under the painful stress condition. It is known that central stimulant drugs such as amphetamine produce central excitant effects by acting mainly on brain stem structures. Bradley (3) showed neurons affected by D-amphetamine to be also sensitive to noradrenaline -which L-Dopa eventually forms and which can then act directly as a stimulant. The physiological patterns for amphetamine and L-Dopa are similar. Since Krnjevic (13) found dopamine to be the most effective catecholamine, causing depression of the cerebral cortex neuronal activity, it appears that L-Dopa does not work through this mechanism. This is further supported by the increase of spontaneous fluctuations which is attributed to energizers of the cerebral cortex. Thus electrophysiologically it seems that L-Dopa stimulates the cerebral cortex. This supports previous evidence that oral L-Dopa acts through norepinephrine rather than dopamine.
The increase in sexual interest observed and reported by some of our patients occurred at 2 gm of L-Dopa, and confirmed previous findings described in the literature of Parkinson patients who had been treated with L-Dopa (16). However, it is possible that the feeling of well-being experienced 55-127 by the patients due to neurological improvement is the cause of the sexual drive. But as these cases were not Parkinsonians this may entail a different explanation. The sexual urge is elicited by stimulation of the hypothalamus, either directly or indirectly. Indirectly the sensory input is perceived in the posterior part of the frontal lobe and then proceeds to stimulate the hypothalamus. In two of these cases concurrent mood elevation would clinically favour this explanation because the frontal area is concerned with mood changes. It is known that excitation or inhibition of the hypothalamus brings emotional or affective response, seemingly signalling this region as an important control centre for affect.
These perceptual changes -mainly auditory and visual hallucinations which were not hypnagogic in nature, and at times present in patients who previously did not hallucinate -are of interest. The clinical evaluation of the thought process became difficult, particularly when patients were very paranoid and therefore guarded. Also, even in communicative patients measuring modifications in thought content is no simple task, especially when there is a minimal pathological baseline. As a result it was necessary to limit observations to gross changes.
Zimmerman and Burgemeister use the term 'emotional governor' for the effect of tranquillizers and stimulants, and they add that behavioural changes are quantitative rather than qualitative (22) . They also reported that affective and behavioural elements change, while ideation remains the same. Consequently, in a delusional process only the affect regarding the delusion is changed. This hypothesis would assist in interpreting L-Dopa symptoms as a hypothalamic rather than a cortical response. The increase in verbal communication could be an alternative in explaining the new aggravation of their psychosis, whereby some psychotic symptoms otherwise repressed become freely externalized. Another explanation is a direct action of L-Dopa in the basal ganglia region. It is known that stimulation or lesions in the caudate can cause gross behavioural changes (1, 7) . Also, stimulation of the caudate nucleus head in man produces transitory amnesia (during stimulation), speech disorder, euphoria and absence of response to auditory and/ or visual stimuli (20) . A relationship between the caudate nucleus and schizophrenia was suggested by various investigators (6) . The coexistence of psychosis or psychiatric symptoms is not uncommon in Parkinson's disease and in other diseases which destroy basal ganglia tissue, such as carbon monoxide and manganese poisoning. If there is a more basic relationship between neurological and psychiatric symptoms it has yet to be determined. Some investigators have observed a correlation between the onset of psychiatric symptoms during levodopa therapy and improvement or worsening of the Parkinsonian symptomatology (6, 21) . It Should be remembered that phenothiazine therapy is claimed to be most effective if a slight Parkinson's state is induced.
Another explanation for the incidence of psychiatric symptoms during levodopa therapy might be the biochemical theories of schizophrenia related to the catecholamine metabolism. Since the earliest work of Cameron, who established the relationship between the adrenal glands and emotions (5), several theories have been offered. Osmond and Smythies suggested that schizophrenia is the result of a metabolic aberration of the catecho1amines (17) . Hoffer suggested that oxidized derivatives of epinephrine were causal factors ( 11) . Harley Mason suggested that 3-4 dimethoxypheny-1ethylamine (DMPEA) caused psychopathological disturbances (10) . This compound was found in the urine of schizophrenics by Friedhoff and Van Winkle (9) . All these observations would indicate and reflect the presence of an aberrant metabolic pathway of an endogenous psychotogen. Also the structural similarities between L-Dopa and certain hallucinogenic drugs, such as mescaline and its derivatives, have been used to develop theories of the hallucinogenic phenomena by Shulgin et at. (19) .
It must not be forgotten that L-Dopa constitutes part of the chemistry of the human body and that when given in amounts which surpass the normal levels a psychotomimetic action may be elicited. Therefore L-Dopa can be a better substance for the production of a biochemical model for psychosis, and in this way introduce a new approach for the understanding of mental illness.
